Companies
I-Mab Shifts Focus; Divests Chinese Operations to Propel U.S. Biotech Ambitions
In a strategic move to bolster its presence in the U.S. biotech landscape, I-Mab (NASDAQ: IMAB), a renowned global biotech...
3M M Modal Fluency for Imaging Clinches 1 Best in KLAS Award for Fourth Consecutive Year
3M Health Information Systems (HIS) proudly announces that its cutting-edge solution, 3M M Modal Fluency for Imaging, has secured the...
Regenxbio’s RGX-121 Trial Achieves Major Milestone in Hunter Syndrome Treatment
Regenxbio Inc. (Nasdaq: RGNX) has announced significant progress in its Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of...
